An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer-Reference-Cited by-同舟云学术

An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer

Published:2012-12 Issue:6 Volume:21 Page:716-723
ISSN:0960-9776
Container-title:The Breast
language:en
Short-container-title:The Breast

Author:

Cardoso Fatima,Canon Jean-Luc,Amadori Dino,Aldrighetti Daniela,Machiels Jean-Pascal,Bouko Yasmina,Verkh Lev,Usari Tiziana,Kern Kenneth A.,Giorgetti Carla,Dirix Luc

Publisher

Elsevier BV

Subject

General Medicine,Surgery

Reference38 articles.

1. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer;Esteva;Journal of Clinical Oncology,2002

2. Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial;Tedesco;Journal of Clinical Oncology,2004

3. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group;Marty;Journal of Clinical Oncology,2005

4. A phase II trial of docetaxel and Herceptin in metastatic breast cancer patients overexpressing HER-2;Kuzur;Proceedings of the American Society of Clinical Oncology,2000

5. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2;Slamon;New England Journal of Medicine,2001

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. NMSDR: Drug repurposing approach based on transcriptome data and network module similarity;Molecular Informatics;2023-01-31

2. Vascular Endothelial Growth Factor Receptors [VEGFR] as Target in Breast Cancer Treatment: Current Status in Preclinical and Clinical Studies and Future Directions;Current Topics in Medicinal Chemistry;2022-04

3. Diverse roles of tumor-stromal PDGFB-to-PDGFRβ signaling in breast cancer growth and metastasis;Advances in Cancer Research;2022

4. Angiogenesis Inhibition in Breast Cancer;Breast Disease;2019

5. Novel Non–HER2-targeted Therapies in HER2+ Breast Cancer;Her2-Positive Breast Cancer;2019